Abridge

TL;DR. Abridge is an ambient AI company founded in 2018 by cardiologist Shiv Rao. Its software converts clinician-patient conversations into structured clinical notes inside Epic workflows. Abridge sells enterprise subscriptions to health systems. More than 200 U.S. health systems used it by October 2025. It fits large provider organizations, not individual clinicians.

At a Glance

Abridge makes one defining bet. It bets that the clinical conversation can power medical documentation and downstream health-system workflows. Abridge was founded in Pittsburgh in 2018. It builds ambient AI software for electronic health record workflows. The software turns clinician-patient conversations into structured notes.

Practicing cardiologist Shiv Rao founded the company to address clinicians’ documentation burden. Rao remains CEO. Early technical leadership included Carnegie Mellon researcher Zachary Lipton. Abridge positions itself in healthcare AI. Its Series E strategy extends from clinical notes into revenue-cycle intelligence. Revenue-cycle intelligence supports coding and billing workflows.

In June 2025, Abridge announced a $300 million Series E. Andreessen Horowitz led the round, and Khosla Ventures participated. Reports placed its valuation at $5.3 billion. Publicly reported Series B, C, D, and E rounds total at least $730 million. This total excludes earlier capital.

Abridge’s February 2024 announcement confirms a $30 million Series B and $150 million Series C. Sacra reports a $250 million Series D in February 2025. Pittsburgh is its founding base. I could not verify a current employee count from the reliable sources I reviewed.

Abridge says its platform was deployed across more than 150 enterprise health systems by June 2025. Useful links: website, about, product, and blog. Company pages reviewed did not identify public developer documentation or an official GitHub repository.

Primary sources: founders, Series E, valuation, and clinical study.

Adoption & Sentiment

Abridge’s clearest external recognition is its 2025 Best in KLAS award for Ambient AI, based on customer feedback. The research team could not verify a current G2 rating or review count.

Adoption is strongest in large health systems. Abridge reported serving more than 200 systems in its October 2025 UPMC announcement. UPMC planned to expand access to 12,000 clinicians by 2026. Abridge’s Sutter case study says the system reached 1,000+ clinicians within three months. The company reports 78% improved work satisfaction, 59% improved note quality, and 53% increased undivided patient attention.

The case page omits survey sample size and methodology, so treat these as vendor-reported results. Sutter clinicians quoted there describe more patient focus and feeling less rushed.

Public feedback remains limited. Selected customer stories do not reveal typical editing effort or complaint rates. Enterprise health-system rollouts dominate the available adoption evidence. Little public evidence covers clinicians outside those deployments.

How It Makes Money

Abridge sells enterprise subscriptions to healthcare organizations, with prospective buyers directed to contact its team. Its product and contact pages do not list standard prices, a free tier, or a trial. Sacra describes a B2B SaaS model, with licenses scaled by clinician count or encounter volume and integration complexity. Abridge has not disclosed a standard per-clinician rate, so third-party price estimates remain unverified.

Reported revenue measures show rapid scale but are not directly interchangeable. Sacra estimated $100 million in ARR in May 2025, up from its $60 million estimate at year-end 2024. TechCrunch reported $117 million in contracted ARR in Q1 2025, citing The Information. That contracted figure included signed contracts for customers not yet onboarded, so it is not equivalent to realized revenue.

Abridge announced a $300 million Series E in June 2025, and TechCrunch reported a $5.3 billion valuation. For market context, Abridge says U.S. healthcare spends nearly $1.5 trillion annually on administrative costs. That spending figure is broad industry context, not a company-disclosed TAM or revenue forecast. The available evidence points to an enterprise-focused, venture-backed growth stage. The cited sources do not establish audited current revenue or a formal TAM.

Classification

Classify Abridge primarily as AI Healthcare. Its ambient generative AI converts patient-clinician conversations into structured notes and places drafts within electronic health record (EHR) workflows. A January 29, 2025 announcement names Epic’s ASAP module, Haiku, and Hyperspace integrations for emergency care. These capabilities make clinical documentation and EHR workflow integration more precise descriptors than general-purpose AI chat.

Primary Category: AI Healthcare Categories: AI Healthcare Tags: ambient ai, generative ai, medical scribe, clinical documentation, electronic health records, epic integration, clinical workflow, health systems, clinicians, multilingual

Leadership & Team

Abridge’s leadership combines a clinician-founder, senior AI researchers, and operators from high-growth technology companies. Its clearest recent executive addition is Sagar Sanghvi. Abridge appointed him its first CFO on January 31, 2025. He previously held leadership roles at Accel and Instacart.

Abridge’s published culture principles emphasize action, continuous learning, teamwork, user empathy, and trust. The company describes its work culture as blameless. It describes its success as a team effort. The leadership and culture pages I reviewed publish no employee count. So I cannot verify team size and growth here.

For governance, Abridge announced in the 2024 Series C release that Lightspeed Venture Partners would join its board. That release identifies Paul Ricci as a Lightspeed advisor and former Nuance chairman and CEO. It does not identify him as an Abridge board member.

Impact & Recommendations

Abridge's clearest impact signal is operational: a WashU/BJC pilot found documentation time fell 15% by day 150. After-hours documentation fell 20%, and the system expanded from 450 pilot clinicians to approximately 4,000 users. These partner-reported outcomes show scaling demand, but one system's pilot cannot establish general or lasting effects. Yale researchers reported adjusted burnout odds 74% lower after 30 days of Abridge use. That observational study supports promise, not proof of durable causal benefit.

Abridge reported a $300 million Series E in 2025 and more than 150 enterprise health-system partners. An installed enterprise footprint, EHR workflow integration, and clinician-led quality testing form its strongest potential moat. Expansion beyond note drafting into coding and revenue-cycle workflows could deepen value, but raises execution and trust stakes.

Competition includes Epic's ambient documentation, plus Nabla and Suki in clinical documentation. Epic's EHR control creates a distribution threat; smaller rivals compete on usability, price, and specialty coverage. Abridge's reported enterprise reach differentiates it, while buyers still need to validate outcomes locally.

Best fit: large health systems with heavy documentation burden, complex specialties, and capacity for enterprise change management. Shortlist Abridge for a structured pilot, not blanket deployment. Track note edits, after-hours time, adoption, patient experience, and coding quality. Outlook is positive if time savings persist and broader workflows prove reliable.

What It Offers

Epic workflow integration is Abridge’s clearest product differentiator. Clinicians record in Haiku and review AI-drafted notes in Hyperspace. Abridge sells an enterprise clinical documentation platform. Its public product pages direct health systems to contact sales. They do not list prices or self-serve tiers.

The platform converts clinician-patient conversations into structured, specialty-aware notes. Its Contextual Reasoning Engine adds prior encounter information, health-system guidelines, and clinician preferences. Linked Evidence connects generated note content to its source information for clinician review. The system can also identify problems aligned with billing codes and surface EHR-integrated orders for review.

Abridge announced its Emergency Medicine release on January 29, 2025. It integrates with Epic’s ASAP module in Haiku and Hyperspace. It lets clinicians start recordings from the emergency department Track Board. On June 18, 2025, Abridge announced inpatient documentation and an outpatient-orders pilot. Both came through Epic’s Workshop program.

Inpatient workflows support H&P, progress, and consult notes. The initial outpatient pilot surfaces medications discussed during visits. Abridge described imaging and lab orders as future additions.

Abridge announced nursing workflow development with Mayo Clinic and Epic in July 2024. That announcement described collaborative design and testing, not general product availability. Abridge’s documented access model centers on mobile recording through Epic Haiku and note review in Hyperspace. Publicly available materials reviewed here do not specify list pricing, a public developer API, or a standalone developer tier.

Who It's Built For

Abridge’s clearest fit is large, multisite health systems. By October 2025, the company reported adoption across more than 200 U.S. health systems. UPMC planned expansion to 12,000 clinicians by 2026, while Mayo Clinic’s enterprise agreement began with approximately 2,000 clinicians.

Public deployments point to institutional health-system customers and clinician users, rather than a consumer-first market. Physicians and other clinicians use the product. Nursing documentation is also a target workflow, including work developed with Mayo Clinic and Epic. Enterprise IT and implementation teams are relevant stakeholders because Abridge integrates with EHR workflows and offers centralized deployment controls.

Common use cases include:

• Capturing patient conversations and drafting clinical notes.

• Bringing relevant patient history and prior-visit context into care workflows.

• Producing actionable encounter outputs, including orders, for clinician review.

• Linking generated note content to source information so clinicians can verify it.

• Drafting nursing documentation from nurse-patient conversations.

Abridge supports outpatient, emergency, and inpatient care. The company reports support for more than 28 languages and 50 specialties. UPMC reported live use across 44 specialties, including oncology, obstetrics and gynecology, cardiology, and neurology. These examples suggest a broad clinical remit, including pediatric care at UPMC Children’s Hospital of Pittsburgh.

The strongest documented fit is enterprise-scale provider organizations. Abridge states no employee threshold. Geographic emphasis is the United States. Abridge reported more than 200 U.S. health-system customers. Kaiser Permanente made the tool available across 40 hospitals and more than 600 medical offices. These sites span eight states and Washington, D.C.

Security & Compliance

Abridge publicly reports SOC 2 Type II coverage. It also reports 256-bit encryption for data in transit and at rest. Its enterprise materials say data stays in secure U.S.-based data centers. Detailed audit evidence requires a Trust Center request.

Abridge’s Trust Center says an independent third-party auditor validated its SOC 2 Type II report for security and confidentiality. Abridge describes its enterprise technology as HIPAA-compliant, but HIPAA is a legal framework, not a certification. The product page describes enterprise access management, configurable compliance and data-governance controls, and centralized usage monitoring. It does not publicly specify SSO, role-based permissions, audit-log features, or data residency outside the United States.

The August 2025 privacy policy says Abridge collects and shares personal health data with consent. It says users can delete recordings or accounts. It says Abridge does not sell personal data. It says research uses de-identified health data or external data obtained with consent. Abridge says it seeks consent before using personal data for research.

These statements describe the published policy. Customer-specific enterprise terms may differ.

Abridge describes clinical safeguards for generated notes. Its published research outlines a proprietary model that detects unsupported claims and automated correction using transcript and EHR context. The company reports more than 1,000 hours of human validation for its guardrails. Clinicians can check note content against the source transcript and audio before signing.

The public materials I reviewed did not establish ISO 27001 or HITRUST certification. They did not establish specific retention periods for enterprise audio. They did not establish a disclosed security breach. Abridge makes its SOC 2 report available by request through its Trust Center.

Chiri Analysis

Chiri Score: 79/100

Verdict

Best for:

• Large multisite U.S. health systems running Epic

• Organizations with heavy clinician documentation burden and after-hours charting

• Systems covering outpatient, emergency, inpatient, and nursing workflows

• Buyers with capacity for structured pilots and enterprise change management

• Teams that require note-to-source auditability before signing

Not for:

• Individual clinicians or small practices seeking self-serve sign-up

• Buyers needing published pricing or a free trial

• Organizations requiring data residency outside the United States

• Developers seeking a public API or developer tier

• Buyers requiring ISO 27001 or HITRUST certification as a precondition

Head-to-head

Frequently Asked Questions

What does Abridge do?

Abridge builds ambient AI, meaning software that listens to clinical visits in the background. It turns clinician-patient conversations into structured clinical notes. Clinicians capture visits in Epic Haiku and review drafts in Epic Hyperspace. Linked Evidence ties each note statement to its source for verification.

Is Abridge SOC 2 compliant?

Yes. Abridge states an independent auditor validated its SOC 2 Type II report for security and confidentiality. Buyers request the report through its Trust Center. Abridge also describes its enterprise technology as HIPAA-compliant. Public materials do not establish ISO 27001 or HITRUST certification.

How much does Abridge cost?

Abridge does not publish prices. It lists no free tier, trial, or self-serve plan. Buyers contact sales for an enterprise subscription. Sacra reports pricing scales with clinician count or encounter volume and integration complexity.

Is Abridge good for enterprise health systems?

Yes. Enterprise health systems are its core market. Kaiser Permanente, Mayo Clinic, UPMC, and Sutter run Abridge deployments. UPMC planned access for 12,000 clinicians by 2026. Abridge received the 2025 Best in KLAS award for Ambient AI.

Who are Abridge's competitors?

Abridge competes with Epic's own ambient documentation, Nabla, and Suki. Epic holds a distribution advantage through EHR control. Nabla and Suki compete on usability, price, and specialty coverage. Abridge differentiates on enterprise reach and deep Epic workflow integration.

Does Abridge integrate with Epic?

Yes. Abridge integrates with Epic Haiku for capture and Hyperspace for note review. In January 2025 it added emergency care support through Epic's ASAP module. Mayo Clinic nursing work came through the Epic Workshop program.

Does Abridge reduce documentation time?

A WashU Medicine and BJC Health evaluation reported a 15% documentation time reduction by day 150. After-hours documentation fell by up to 20%. That deployment grew from 450 to about 4,000 clinicians. Results come from one system and need local validation.

How fast is Abridge growing?

Sacra estimated Abridge ARR at $100 million in May 2025. That figure rose from an estimated $60 million at year-end 2024. Abridge raised a $300 million Series E in June 2025. TechCrunch reported a $5.3 billion valuation.

---

Reviewed by Chiri Atlas Research Desk (AI Tooling Analyst) on 2026-10-02.